The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Checkpoint inhibitor treatment in patients with isolated in-transit melanoma metastases.
 
Lucy Storey
No Relationships to Disclose
 
Mohammed Abdul-Latif
No Relationships to Disclose
 
Sophia Kreft
No Relationships to Disclose
 
Emma Barrett
No Relationships to Disclose
 
Lisa M Pickering
No Relationships to Disclose
 
Maartje W. Rohaan
No Relationships to Disclose
 
Sobia Ahmed
No Relationships to Disclose
 
Thomas K. Eigentler
Consulting or Advisory Role - Bristol-Myers Squibb; LEO Pharma; MSD; Novartis; Pierre Fabre; Roche Pharma AG; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Roche Pharma AG
 
Jessica Cecile Hassel
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD; Pierre Fabre; Sun Pharma
Research Funding - 4SC (Inst); Amgen (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Idera (Inst); Immunocore (Inst); Novartis (Inst); Philogen (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Pierre Fabre
 
Sebastian Haferkamp
Honoraria - Amgen; Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - AMGEN; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
 
Frank Meiss
Honoraria - Bristol-Myers Squibb; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pierre Fabre; Roche Pharma AG
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pierre Fabre
 
Theresa Steeb
No Relationships to Disclose
 
Heather May Shaw
Consulting or Advisory Role - Bristol-Myers Squibb; Genzyme; MSD Oncology; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Sanofi
Research Funding - Genmab (Inst); Idera (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genmab; Idera; Iovance Biotherapeutics; Merck Sharp & Dohme; Novartis; Roche
 
Christian U. Blank
Stock and Other Ownership Interests - Forty Seven; Neon Therapeutics; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Sanofi (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
James M. G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
 
Bastian Schilling
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pfizer/EMD Serono; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
 
Paul Lorigan
Honoraria - Amgen; Bristol-Myers Squibb; Merck; MSD; NeraCare GmbH; Novartis; Oncology Education; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Paul D. Nathan
Consulting or Advisory Role - 4SC; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD